Baxter: Baxter reorganizes to two segments, recasts prior-period segment results and discloses operational/organic sales metrics

Baxter changed its reportable segments to Medical Products & Therapies and Healthcare Systems & Technologies and recast prior-period segment and product-category financials for comparability. Key Highlights: Company moved from three reportable segments to two: Medical Products & Therapies (with Infusion Therapies & Platforms and Advanced Surgery) and Healthcare Systems & Technologies. Former Pharmaceuticals segment now reported within the Infusion Therapies & Platforms division of Medical Products & Therapies; Certain manufacturing-related sales moved from Other into that division. Updated corporate cost allocation: some shared corporate expenses will remain unallocated rather than fully allocated to segments going forward. Unaudited recast tables in Exhibit 99.1 present segment net sales, operating income and non-GAAP operational and organic sales growth for specified periods to aid comparability. Company states recast does not change consolidated net income, EPS, total assets or stockholders' equity for prior periods; disclosures will be updated for comparative purposes in future filings. Original SEC Filing: BAXTER INTERNATIONAL INC [ BAX ] - 8-K - Jul. 14, 2026